Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Radiation Injuries 1Prostatic Neoplasms 1Non-alcoholic Fatty Liver Disease 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 593Cyclophosphamide 539Magnetic Resonance Spectroscopy 527Radiotherapy 506Specimen Handling 504Nivolumab 406Cisplatin 370Carboplatin 360Biopsy 306Blood Specimen Collection 296Radiosurgery 284Paclitaxel 276Surveys and Questionnaires 269Standard of Care 267Gemcitabine 266fludarabine 261Dexamethasone 258Drug Therapy 256Bevacizumab 248venetoclax 247Oxaliplatin 206Rituximab 197Capecitabine 194Radiation 190Fluorouracil 186Ipilimumab 183durvalumab 181Doxorubicin 174atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lisinopril × 1 year × Clear all
NCT04550481 2026-01-21

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Northwestern University

Phase 2 Active not recruiting
45 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease

NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡